10 April 2019 in Urologiia
FAF.R. AsfandiyarOv AsfandiyarOv
F.R. AsfandiyarOv AsfandiyarOv
ISI.S. Shormanov Shormanov
+7
In this study an attempt was made to determine some reasons that prompted the urologist to make a choice in favor of particular drug or combination from a wide variety of available drugs. The prescribing habits and subjective evaluation of efficiency and safety of the drugs for the treatment of lower urinary tract symptoms/benign prostatic hyperplasia by the urologists in Russia was analyzed. a prospective multicenter epidemiological study "LUTS/BPH - who treats?" was carried out in 12 centers using data obtained from May 1 to July 31, 2018 with anonymous survey of 500 urologists living in 9 cities of the Russian Federation. The survey consisted of 46 questions reflecting a level of education, involvement in scientific life of urologic community, membership in various professional organizations, and subjective assessment of safety and efficiency of drugs used in Russian Federation for the treatment of urinary disorders. The obtained data was analyzed for a whole group and further in the subgroups. Alpha-blockers are the most commonly prescribed drugs. These drugs constitute 63.4% of all appointments, followed by the 5-a-reductase inhibitors (23.98%) and combined therapy by the both drugs (24.68%). The most frequently used alpha-blocker is tamsulosin, but professors, MD and urologists, who read special literature at a regular basis, prescribed tamsulosin and silodosin equally. In primary cases and in patients with concomitant cardiac pathology, silodosin was prescribed more commonly in comparison with other alpha-blockers. the results of the study indicate a concordance with global trends in the treatment of these patients. Our data reflect a significant influence of the level of education, work experience and involvement in scientific professional life of urologic community on the choice of a particular drug for the treatment of LUTS/BPH and prove the feasibility of further work which should be aimed at popularization of the modern medical knowledges among the urologists and organization of a process of continuous medical education.
1 January 2024 in Russian Journal of Human Reproduction
7 January 2025 in Urology Herald
Cystitis is a common disease worldwide, with up to 36 million cases recorded annually in Russia alone. In 10 % of patients, the condition transforms into a chronic recurrent form. Up to 30 % of visits to outpatient urologists are related to acute or recurrent cystitis. The prevalence of chronic cystitis in women is closely linked to the anatomical and topographical characteristics of the genitourinary system, the presence of gynecological diseases, and hormonal status. Effective treatment for acute or chronic cystitis involves complex therapy, with the key to success lying in the appropriate selection of antibacterial drugs. The current study aimed to analyse the literature data on the effectiveness of Furamag® in the complex treatment of patients with acute and chronic cystitis. To achieve this objective, we conducted a search for articles in scientific databases such as PubMed, Medline, minzdrav.gov.ru, and elibrary.ru using the following keywords: «urinary tract infection», «acute cystitis», «chronic cystitis», «furazidine», «potassium furazidine». Based on the results of our search, we concluded that Furamag® has been successfully used for a long time in the treatment of both acute and chronic cystitis, demonstrating high efficacy and good patient tolerance. This explains its widespread use in routine clinical practice among urologists, gynecologists, and therapists.